相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Targeting Fc Receptor-Mediated Effects and the Don't Eat Me Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Lei Tian et al.
CLINICAL CANCER RESEARCH (2022)
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Histone modifiers at the crossroads of oncolytic and oncogenic viruses
Sara A. Murphy et al.
MOLECULAR THERAPY (2022)
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Giulia Petroni et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Hallmarks of Cancer: New Dimensions
Douglas Hanahan
CANCER DISCOVERY (2022)
Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer
Seoyul Lee et al.
Molecular Therapy-Oncolytics (2022)
Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment
Lihong Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
Roger Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma
Jaime Gallego Perez-Larraya et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Ferroptosis Inducer Improves the Efficacy of Oncolytic Virus-Mediated Cancer Immunotherapy
Weilin Liu et al.
BIOMEDICINES (2022)
Teserpaturev/G47Δ: First Approval
James E. Frampton
BIODRUGS (2022)
The expanding role for small molecules in immuno-oncology
Rienk Offringa et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements
Chae-Ok Yun et al.
FRONTIERS IN IMMUNOLOGY (2022)
Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors
Deli Song et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
CRISPR in cancer biology and therapy
Alyna Katti et al.
NATURE REVIEWS CANCER (2022)
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Qian Wu et al.
ACTA PHARMACOLOGICA SINICA (2021)
Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy
Mathilde Feist et al.
CANCER GENE THERAPY (2021)
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Moshe Talpaz et al.
LEUKEMIA (2021)
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
Pottayil G. Sasikumar et al.
COMMUNICATIONS BIOLOGY (2021)
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
Egle Ramelyte et al.
CANCER CELL (2021)
Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs
Wan-Yu Chen et al.
CANCER LETTERS (2021)
The Identification and Development of a Novel Oncolytic Virus: Alphavirus M1
Jing Cai et al.
HUMAN GENE THERAPY (2021)
Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy
Ying-Chao Duan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
Dan You et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer
Giulia Marelli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity
Min Yang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Tan-Trieu Nguyen et al.
CLINICAL CANCER RESEARCH (2021)
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Enyong Dai et al.
MOLECULAR CANCER (2021)
ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation
Mengjie Hu et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Oncolytic virotherapy as immunotherapy
Alan Melcher et al.
SCIENCE (2021)
An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma
Bo Xu et al.
NATURE COMMUNICATIONS (2021)
Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8+ T Cells
Duo Chen et al.
FRONTIERS IN IMMUNOLOGY (2021)
Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy
Fengling Wang et al.
NEOPLASIA (2021)
A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer
Na Wang et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Julia Maria Ressler et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy
Kevin Chih-Yang Huang et al.
CANCERS (2021)
IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors
Mamoru Tasaki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model
Hai-Jun Hu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Can Biomarkers Guide Oncolytic Virus Immunotherapy?
Howard L. Kaufman
CLINICAL CANCER RESEARCH (2021)
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Rosalin Mishra et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer
Robert Cornelison et al.
CANCERS (2021)
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
Johannes P. W. Heidbuechel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis
Darshak K. Bhatt et al.
VACCINES (2021)
Current developments of targeting the p53 signaling pathway for cancer treatment
Jing Huang
PHARMACOLOGY & THERAPEUTICS (2021)
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
Federica Martorana et al.
FRONTIERS IN PHARMACOLOGY (2021)
STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development
Jessica N. Filderman et al.
FRONTIERS IN IMMUNOLOGY (2021)
Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction
Lincheng Fang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Pacritinib protects dendritic cells more efficiently than ruxolitinib
Annkristin Heine et al.
EXPERIMENTAL HEMATOLOGY (2021)
Oncolytic Bovine Herpesvirus 1 Inhibits Human Lung Adenocarcinoma A549 Cell Proliferation and Tumor Growth by Inducing DNA Damage
Wencai Qiu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies
Walter Hanel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade
Chi Yan et al.
MOLECULAR CANCER (2021)
Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
Hongbo Zhang et al.
MOLECULES (2021)
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
Eric S. Lightcap et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression
Thao Thi Thanh Nguyen et al.
CELL DEATH & DISEASE (2021)
Multifunctional Nanodrug Mediates Synergistic Photodynamic Therapy and MDSCs-Targeting Immunotherapy of Colon Cancer
Dongbing Ding et al.
ADVANCED SCIENCE (2021)
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege
Casey R. Ager et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives
Annalisa Chianese et al.
CANCERS (2021)
Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits
Bart Spiesschaert et al.
CANCERS (2021)
Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
Guoqiang Sun et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Targeting PI3K/Akt signal transduction for cancer therapy
Yan He et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
KRAS mutation: from undruggable to druggable in cancer
Lamei Huang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma
Fan Xing et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Cancer metabolism: looking forward
Inmaculada Martinez-Reyes et al.
NATURE REVIEWS CANCER (2021)
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Turning cold tumors into hot tumors by improving T-cell infiltration
Yuan-Tong Liu et al.
THERANOSTICS (2021)
Systemic immunity in cancer
Kamir J. Hiam-Galvez et al.
NATURE REVIEWS CANCER (2021)
IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Tianyue Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation
Lingjuan Chen et al.
THERANOSTICS (2021)
The emerging role of epigenetic therapeutics in immuno-oncology
Michael J. Topper et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy
Vivek Singh Tomar et al.
CELL BIOLOGY AND TOXICOLOGY (2020)
Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma
Bingtao Tang et al.
CLINICAL CANCER RESEARCH (2020)
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
Arezoo Hosseini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
A phase I/II study of Pexa-Vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer.
M. Cecilia Monge B. et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Brian A. Lanman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Robert H. Jones et al.
LANCET ONCOLOGY (2020)
Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression
Shweta Joshi et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus
Mark S. Ferguson et al.
MOLECULAR THERAPY (2020)
Targeting SHP2 as a promising strategy for cancer immunotherapy
Qianqian Liu et al.
PHARMACOLOGICAL RESEARCH (2020)
Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade
Shinsuke Nakao et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer
Jing Ma et al.
CELL DEATH & DISEASE (2020)
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Yuan Fang et al.
ACTA PHARMACEUTICA SINICA B (2020)
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano-Goroff et al.
CELL RESEARCH (2020)
Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade
Chaolong Lin et al.
CANCER IMMUNOLOGY RESEARCH (2020)
P53: A Guardian of Immunity Becomes Its Saboteur through Mutation
Arjelle Decasa Agupitan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Jing Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Metabolic reprogramming and cancer progression
Brandon Faubert et al.
SCIENCE (2020)
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Christianne Groeneveldt et al.
TRENDS IN IMMUNOLOGY (2020)
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
Guan Wang et al.
NATURE COMMUNICATIONS (2020)
Small molecules, big impact: 20 years of targeted therapy in oncology
Philippe L Bedard et al.
LANCET (2020)
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Alireza Labani-Motlagh et al.
FRONTIERS IN IMMUNOLOGY (2020)
Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety
Yan Ge et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
Dipongkor Saha et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Small molecules targeting the innate immune cGAS-STING-TBK1 signaling pathway
Chunyong Ding et al.
ACTA PHARMACEUTICA SINICA B (2020)
Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
Zong Sheng Guo et al.
BIOMEDICINES (2020)
cGAS-STING, an important pathway in cancer immunotherapy
Minlin Jiang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Oncolytic viruses for cancer immunotherapy
Otto Hemminki et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
The Contribution of Epigenetics to Cancer Immunotherapy
Lorea Villanueva et al.
TRENDS IN IMMUNOLOGY (2020)
Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
Magdalena Konieczny et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
Matthew J. LaMarche et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeting STAT3 in Cancer Immunotherapy
Sailan Zou et al.
MOLECULAR CANCER (2020)
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
Juyan Zheng et al.
MOLECULAR CANCER (2020)
Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1
Jing Cai et al.
MOLECULAR ONCOLOGY (2020)
Targeting the epigenetic regulation of antitumour immunity
Simon J. Hogg et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical landscape of oncolytic virus research in 2020
Nicholas Macedo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus
Guendalina Froechlich et al.
CANCERS (2020)
IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects via Multiple Pathways in Colorectal Cancer
Lili Deng et al.
ONCOLOGY RESEARCH (2020)
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
Bin Zhang et al.
MOLECULAR CANCER (2020)
Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy
Shariful Islam et al.
BLOOD ADVANCES (2020)
Clinical Development of BRAF plus MEK Inhibitor Combinations
Vivek Subbiah et al.
TRENDS IN CANCER (2020)
SnapShot: Cancer Immunotherapy with Oncolytic Viruses
Shashi Gujar et al.
CELL (2019)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
The Antiviral Apparatus: STING and Oncolytic Virus Restriction
Joel Lee et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors
Taylor M. Pearl et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells
Lei Wang et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager
Jana de Sostoa et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Targeting PI3K signaling in cancer: Challenges and advances
Maria Chiara De Santis et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis
Michela Muscolini et al.
JOURNAL OF VIROLOGY (2019)
A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
Pottayil G. Sasikumar et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition
Victoria A. Jennings et al.
MOLECULAR THERAPY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus
Candace R. Fox et al.
VIRUSES-BASEL (2019)
Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
Praveen K. Bommareddy et al.
ONCOIMMUNOLOGY (2019)
Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models
Naiara Martinez-Velez et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Immunogenic cell death in cancer therapy: Present and emerging inducers
Jingyi Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Targeting mTOR for cancer therapy
Hui Hua et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Max D. Wellenstein et al.
NATURE (2019)
Optimizing oncolytic virotherapy in cancer treatment
Kevin Harrington et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
DNA sensing by the cGAS-STING pathway in health and disease
Mona Motwani et al.
NATURE REVIEWS GENETICS (2019)
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Ali S. Alzahrani
SEMINARS IN CANCER BIOLOGY (2019)
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Peng Liu et al.
NATURE COMMUNICATIONS (2019)
Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth
Zhiwen Wu et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma
Haoyu Deng et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
Venkatesh Sivanandam et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer
A. J. Robert McGray et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
Ying Zhang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
STING Restricts oHSV Replication and Spread in Resistant MPNSTs but Is Dispensable for Basal IFN-Stimulated Gene Upregulation
Joel M. Lee et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
Arsen Osipov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse
Tadashi Ashizawa et al.
BIOMEDICAL RESEARCH-TOKYO (2019)
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Longchuan Bai et al.
CANCER CELL (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
Aravindhan Ganesan et al.
SCIENTIFIC REPORTS (2019)
JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models
Manish R. k Patel et al.
CANCER GENE THERAPY (2019)
Mutant p53 as a guardian of the cancer cell
Fiamma Mantovani et al.
CELL DEATH AND DIFFERENTIATION (2019)
The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves
William G. Kerr et al.
JOURNAL OF IMMUNOLOGY (2019)
Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy
Gang Shi et al.
MOLECULAR THERAPY (2019)
HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity
Huanbin Wang et al.
NATURE CHEMICAL BIOLOGY (2019)
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Yichen Xu et al.
NATURE MEDICINE (2019)
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
Jun Wei et al.
NATURE (2019)
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Zong Sheng Guo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Inhibition of p53 inhibitors: progress, challenges and perspectives
Gema Sanz et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
Epigenetic therapy in immune-oncology
Peter A. Jones et al.
NATURE REVIEWS CANCER (2019)
A cautionary note on the selectivity of oncolytic poxviruses
Bingtao Tang et al.
ONCOLYTIC VIROTHERAPY (2019)
Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map
Jennifer Huynh et al.
NATURE REVIEWS CANCER (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non muscle-invasive bladder cancer: Interim results
Vignesh T. Packiam et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines
Stephen J. Russell et al.
CANCER CELL (2018)
Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Dipongkor Saha et al.
CLINICAL CANCER RESEARCH (2018)
Oncolytic Viruses for Tumor Precision Imaging and Radiotherapy
Zi J. Wu et al.
HUMAN GENE THERAPY (2018)
Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors
Madhav D. Sharma et al.
IMMUNITY (2018)
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Dewan Md Sakib Hossain et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
Nikolas Tim Martin et al.
MOLECULAR THERAPY (2018)
Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds
Mohammed Selman et al.
MOLECULAR THERAPY (2018)
Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
Stacy J. Kowalsky et al.
MOLECULAR THERAPY (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Dimethyl fumarate potentiates oncolytic virotherapy through NF-kappa B inhibition
Mohammed Selman et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
David A. Schaer et al.
CELL REPORTS (2018)
Heating it up: Oncolytic viruses make tumors hot' and suitable for checkpoint blockade immunotherapies
Shashi Gujar et al.
ONCOIMMUNOLOGY (2018)
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
Carole Achard et al.
EBIOMEDICINE (2018)
Organoid technology and applications in cancer research
Hanxiao Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong-Ho Cha et al.
MOLECULAR CELL (2018)
Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses
Olga V. Matveeva et al.
REVIEWS IN MEDICAL VIROLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis
Chadi Zakaria et al.
PLOS PATHOGENS (2018)
The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer)
Zong Sheng Guo
BMC CANCER (2018)
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells
Joshua D. Freedman et al.
CANCER RESEARCH (2018)
MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
Praveen K. Bommareddy et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
Zuqiang Liu et al.
NATURE COMMUNICATIONS (2018)
DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage
Xiao Xiao et al.
NATURE COMMUNICATIONS (2018)
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Luca Falzone et al.
FRONTIERS IN PHARMACOLOGY (2018)
Oncolytic viruses as engineering platforms for combination immunotherapy
Kwame Twumasi-Boateng et al.
NATURE REVIEWS CANCER (2018)
Epigenetic control of CD8+ T cell differentiation
Amanda N. Henning et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms
Minah Kim et al.
CANCER RESEARCH (2018)
Integrating oncolytic viruses in combination cancer immunotherapy
Praveen K. Bommareddy et al.
NATURE REVIEWS IMMUNOLOGY (2018)
The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer
Mohammad W. Khan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models
Shinichi Esaki et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso et al.
NATURE (2017)
Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo
Junfen Ma et al.
ONCOLOGY LETTERS (2017)
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
Dmitriy Zamarin et al.
NATURE COMMUNICATIONS (2017)
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies
Edurne San Jose-Eneriz et al.
NATURE COMMUNICATIONS (2017)
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
Zuqiang Liu et al.
NATURE COMMUNICATIONS (2017)
Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation
Mark A. Currier et al.
ONCOTARGET (2017)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
HDAC6 controls innate immune and autophagy responses to TLR-mediated signalling by the intracellular bacteria Listeria monocytogenes
Olga Moreno-Gonzalo et al.
PLOS PATHOGENS (2017)
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma
Alena C. Jaime-Ramirez et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma
Brian Hutzen et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
Oncolytic Viruses in Cancer Treatment A Review
Sean E. Lawler et al.
JAMA ONCOLOGY (2017)
Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies
Sachin R. Jhawar et al.
FRONTIERS IN ONCOLOGY (2017)
Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer
Anwen Howells et al.
FRONTIERS IN ONCOLOGY (2017)
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
Adam C. Palmer et al.
CELL (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma
Patricia A. Corrigan et al.
ANNALS OF PHARMACOTHERAPY (2017)
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies
Amelia Sadie Aitken et al.
BIOMEDICINES (2017)
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
Nisha Nagarsheth et al.
CANCER RESEARCH (2016)
Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
Frederick J. Kohlhapp et al.
CLINICAL CANCER RESEARCH (2016)
The Roles of MDM2 and MDMX in Cancer
Orit Karni-Schmidt et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11 (2016)
Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent
Michael Xiang et al.
BLOOD (2016)
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim et al.
CANCER CELL (2016)
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Sai Krishna Athuluri-Divakar et al.
CELL (2016)
The Emerging Hallmarks of Cancer Metabolism
Natalya N. Pavlova et al.
CELL METABOLISM (2016)
Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus
Tim Patrick Ellerhoff et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma
Andrew Stiff et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Megan M. Kaneda et al.
CANCER DISCOVERY (2016)
Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer
Lily Francis et al.
ONCOTARGET (2016)
Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis
Michelle J. Wilkinson et al.
ONCOTARGET (2016)
First-in-class small molecule potentiators of cancer virotherapy
Mark H. Dornan et al.
SCIENTIFIC REPORTS (2016)
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Hengrui Zhu et al.
CELL REPORTS (2016)
Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy
Marcin P. Komorowski et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy
Hao-Nan Chang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy
I. D. Iankov et al.
CANCER GENE THERAPY (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis
E. N. Klein Hesselink et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Metabolic Reprogramming of Immune Cells in Cancer Progression
Subhra K. Biswas
IMMUNITY (2015)
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma
Hiroshi Nakashima et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Targeting cancer with kinase inhibitors
Stefan Gross et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress
Victoria Roulstone et al.
MOLECULAR THERAPY (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
Lotte M. E. Berghauser Pont et al.
PLOS ONE (2015)
Signal Transduction in Cancer
Richard Sever et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2015)
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
Ilkka Liikanen et al.
ONCOIMMUNOLOGY (2015)
cu Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction
Ravikumar Muthuswamy et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Modulation of immune cell functions by the E3 ligase Cbl-b
Christina Lutz-Nicoladoni et al.
FRONTIERS IN ONCOLOGY (2015)
A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer
Louisa S. Chard et al.
CLINICAL CANCER RESEARCH (2015)
Epigenetic control of myeloid cell differentiation, identity and function
Damiana Alvarez-Errico et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Combination Treatment of Human Pancreatic Cancer Xenograft Models with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib and Oncolytic Herpes Simplex Virus HF10
Kazuo Yamamura et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells
Ke Jiang et al.
BMC CANCER (2014)
Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land
Z. S. Guo et al.
CANCER GENE THERAPY (2014)
Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency
Alexander Muik et al.
CANCER RESEARCH (2014)
Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors
Nobuhiro Nishio et al.
CANCER RESEARCH (2014)
Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer
Sepideh Gholami et al.
FASEB JOURNAL (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies
Samuel T. Workenhe et al.
MOLECULAR THERAPY (2014)
T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy
Feng Yu et al.
MOLECULAR THERAPY (2014)
PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus
Yin Tong et al.
ONCOLOGY REPORTS (2014)
AKT mediates actinomycin D-induced p53 expression
Chih-Shou Chen et al.
ONCOTARGET (2014)
Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses
Andrew Zloza et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Activated Ras signaling pathways and reovirus oncolysis an update on the mechanism of preferential reovirus replication in cancer cells
Jun Gong et al.
FRONTIERS IN ONCOLOGY (2014)
Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity
Zong Sheng Guo et al.
FRONTIERS IN ONCOLOGY (2014)
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
Annkristin Heine et al.
BLOOD (2013)
Measles virus causes immunogenic cell death in human melanoma
O. G. Donnelly et al.
GENE THERAPY (2013)
The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy
So Y. Kim et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Oncolytic viruses as therapeutic cancer vaccines
David L. Bartlett et al.
MOLECULAR CANCER (2013)
HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy
Byram W. Bridle et al.
MOLECULAR THERAPY (2013)
Suppression of Antiviral Innate Immunity by Sunitinib Enhances Oncolytic Virotherapy
Babal K. Jha et al.
MOLECULAR THERAPY (2013)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo et al.
NATURE MEDICINE (2013)
Oncolytic Vaccinia virus and radiotherapy in head and neck cancer
D. Mansfield et al.
ORAL ONCOLOGY (2013)
Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases
Margaret Gil et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Epigenetic Reprogramming in Cancer
Mario L. Suva et al.
SCIENCE (2013)
Exploiting tumor epigenetics to improve oncolytic virotherapy
Nicole E. Forbes et al.
Frontiers in Genetics (2013)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
HPK1 as a novel target for cancer immunotherapy
Sansana Sawasdikosol et al.
IMMUNOLOGIC RESEARCH (2012)
The mTOR Signalling Pathway in Human Cancer
Helena Populo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Swen Hoelder et al.
MOLECULAR ONCOLOGY (2012)
The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
Kelley A. Parato et al.
MOLECULAR THERAPY (2012)
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
Xiaolei Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Evolutionary conflicts between viruses and restriction factors shape immunity
Nisha K. Duggal et al.
NATURE REVIEWS IMMUNOLOGY (2012)
A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells
Ryuichi Kanai et al.
CLINICAL CANCER RESEARCH (2011)
Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication
Xinping Fu et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Targeting Tumor Vasculature With an Oncolytic Virus
Caroline J. Breitbach et al.
MOLECULAR THERAPY (2011)
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
Jeong Heo et al.
MOLECULAR THERAPY (2011)
Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
Howard L. Kaufman et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Myxoma Virus Virotherapy for Glioma in Immunocompetent Animal Models: Optimizing Administration Routes and Synergy with Rapamycin
XueQing Lun et al.
CANCER RESEARCH (2010)
A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers
Jean-Simon Diallo et al.
MOLECULAR THERAPY (2010)
Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma
XueQing Lun et al.
MOLECULAR THERAPY (2010)
Intelligent Design: Combination Therapy With Oncolytic Viruses
Kathryn Ottolino-Perry et al.
MOLECULAR THERAPY (2010)
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production
Tommy Alain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mutant p53 Gain-of-Function in Cancer
Moshe Oren et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Therapeutic antibodies: successes, limitations and hopes for the future
Patrick Chames et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Specific activation of the p53 pathway by low dose actinomycin D A new route to p53 based cyclotherapy
Meng Ling Choong et al.
CELL CYCLE (2009)
Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide
Xue Qing Lun et al.
CLINICAL CANCER RESEARCH (2009)
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
Michael Haberland et al.
NATURE REVIEWS GENETICS (2009)
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells
Laura Menotti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Targeting the Stroma by T Cells to Limit Tumor Growth
Bin Zhang
CANCER RESEARCH (2008)
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma
F. Errington et al.
GENE THERAPY (2008)
Oncolytic virotherapy as a personalized cancer vaccine
Qi-Xiang Li et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
Thi Lien-Anh Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells
Hua Xiong et al.
NEOPLASIA (2008)
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin
Xue Qing Lun et al.
CANCER RESEARCH (2007)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells
Stefanie Loeser et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells
Marianne M. Stanford et al.
JOURNAL OF VIROLOGY (2007)
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model
Yonatan Y. Mahller et al.
MOLECULAR THERAPY (2007)
History of oncolytic viruses: Genesis to genetic engineering
Elizabeth Kelly et al.
MOLECULAR THERAPY (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model
ZS Guo et al.
CANCER RESEARCH (2006)
Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer
M Shmulevitz et al.
ONCOGENE (2005)
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2
ZS Guo et al.
CANCER RESEARCH (2005)
RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer
K Homicsko et al.
CANCER RESEARCH (2005)
α-type-1 polarized dendritic cells:: A novel immunization tool with optimized CTL-inducing activity
RB Mailliard et al.
CANCER RESEARCH (2004)
5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation:: mechanistic studies and their implications for cancer therapy
JK Christman
ONCOGENE (2002)
A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes
JF Carew et al.
MOLECULAR THERAPY (2001)